Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 8Breast 8Gynecologic 7Tumor-Agnostic 6Plasma cell 6Gastrointestinal 6Myeloid 5CNS 5Dermatologic 4Genitourinary 3Thoracic 2Sarcoma 2Head & Neck 2Other solid neoplasm 1Other neoplasm 1NET 1Endocrine 1

Conditions

Vomiting 1Thyroid Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Ondansetron × Head & Neck × Clear all
NCT06697782 2025-01-22

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 4 Completed
600 enrolled
Head & Neck

Thyroid Neoplasms

NCT03572829 2020-07-15

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

ChineseAMS

Phase 2 Completed
44 enrolled
Head & Neck

Head and Neck Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡